These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9543692)

  • 61. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment.
    Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
    Thyroid; 2005 Apr; 15(4):358-63. PubMed ID: 15876160
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Serum gelatinases (MMP-2 and MMP-9) and VCAM-1 as a guideline in a therapeutic approach in Graves' ophthalmopathy.
    Myśliwiec J; Adamczyk M; Pawłowski P; Nikołajuk A; Górska M
    Endokrynol Pol; 2007; 58(2):105-9. PubMed ID: 17578825
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Smoking was associated with poor response to intravenous steroids therapy in Graves' ophthalmopathy.
    Xing L; Ye L; Zhu W; Shen L; Huang F; Jiao Q; Zhou X; Wang S; Wang W; Ning G
    Br J Ophthalmol; 2015 Dec; 99(12):1686-91. PubMed ID: 26061160
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [The effects of intensive DMPA regimen in the treatment of Graves' ophthalmopathy].
    Wei S; Tong N; Luo Q; Tian H; Yu Y; Liu Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1996 Sep; 27(3):306-9. PubMed ID: 9389069
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical outcomes of orbital irradiation combined with or without systemic high-dose or pulsed corticosteroids for Graves' ophthalmopathy.
    Tsujino K; Hirota S; Hagiwara M; Fukada S; Takada Y; Hishikawa Y; Kono M; Abe M
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):857-64. PubMed ID: 11020584
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy.
    Ujhelyi B; Erdei A; Galuska L; Varga J; Szabados L; Balazs E; Bodor M; Cseke B; Karanyi Z; Leovey A; Mezosi E; Burman KD; Berta A; Nagy EV
    Thyroid; 2009 Apr; 19(4):375-80. PubMed ID: 19355827
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Serum Fas in patients with Graves' ophthalmopathy as a marker of activity of the ocular inflammatory infiltration].
    Myśliwiec J; Kretowski A; Stepień A; Okłota M; Kinalska I
    Pol Merkur Lekarski; 2004 Oct; 17(100):368-70. PubMed ID: 15690704
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy.
    Kung AW; Michon J; Tai KS; Chan FL
    Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy.
    Hiromatsu Y; Kojima K; Ishisaka N; Tanaka K; Sato M; Nonaka K; Nishimura H; Nishida H
    Thyroid; 1992; 2(4):299-305. PubMed ID: 1493371
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transforming growth factor β1 (TGFβ1) and vascular endothelial growth factor (VEGF) in the blood of healthy people and patients with Graves' orbitopathy--a new mechanism of glucocorticoids action?
    Kajdaniuk D; Marek B; Niedziołka-Zielonka D; Foltyn W; Nowak M; Siemińska L; Borgiel-Marek H; Głogowska-Szeląg J; Ostrowska Z; Drożdż L; Kos-Kudła B
    Endokrynol Pol; 2014; 65(5):348-56. PubMed ID: 25301484
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study.
    Marcocci C; Bartalena L; Panicucci M; Marconcini C; Cartei F; Cavallacci G; Laddaga M; Campobasso G; Baschieri L; Pinchera A
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):33-42. PubMed ID: 3308192
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone: a comparison of two dosing regimens.
    Sánchez-Ortiga R; Moreno-Pérez O; González Sánchez V; Arias Mendoza N; Mauri Dot M; Alfayate Guerra R; López Macia A; Picó Alfonso A
    Endocrinol Nutr; 2009 Mar; 56(3):118-22. PubMed ID: 19627724
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Plasma exchange therapy for severe Graves' ophthalmopathy.
    Glinoer D; Schrooyen M
    Horm Res; 1987; 26(1-4):184-9. PubMed ID: 3596467
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy.
    Guy JR; Fagien S; Donovan JP; Rubin ML
    Ophthalmology; 1989 Jul; 96(7):1048-52; discussion 1052-3. PubMed ID: 2771352
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [The assessment of urinary glycosaminoglycans (GAG) excretion during therapy of patients with progressive Graves' ophthalmopathy].
    Pilarska K; Kulig G; Krzystolik Z
    Pol Arch Med Wewn; 2001 Feb; 105(2):139-44. PubMed ID: 11505748
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves.
    Marinò M; Morabito E; Altea MA; Ambrogini E; Oliveri F; Brunetto MR; Pollina LE; Campani D; Vitti P; Bartalena L; Pincheral A; Marcocci C
    J Endocrinol Invest; 2005 Mar; 28(3):280-4. PubMed ID: 15952415
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.
    Le Moli R; Baldeschi L; Saeed P; Regensburg N; Mourits MP; Wiersinga WM
    Thyroid; 2007 Apr; 17(4):357-62. PubMed ID: 17465867
    [TBL] [Abstract][Full Text] [Related]  

  • 78. High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII.
    Miśkiewicz P; Milczarek-Banach J; Rutkowska-Hinc B; Kondracka A; Bednarczuk T
    J Endocrinol Invest; 2019 Feb; 42(2):217-225. PubMed ID: 29949121
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review.
    Zoubek ME; Pinazo-Bandera J; Ortega-Alonso A; Hernández N; Crespo J; Contreras F; Medina-Cáliz I; Sanabria-Cabrera J; Sanjuan-Jiménez R; González-Jiménez A; García-Cortés M; Lucena MI; Andrade RJ; Robles-Díaz M
    United European Gastroenterol J; 2019 Jul; 7(6):825-837. PubMed ID: 31316787
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and safety of low dose oral prednisolone as compared to pulse intravenous methylprednisolone in managing moderate severe Graves' orbitopathy: A randomized controlled trial.
    Roy A; Dutta D; Ghosh S; Mukhopadhyay P; Mukhopadhyay S; Chowdhury S
    Indian J Endocrinol Metab; 2015; 19(3):351-8. PubMed ID: 25932389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.